论文部分内容阅读
目的研究丹参酮ⅡA磺酸钠注射液治疗脑梗死的临床效果。方法 92例脑梗死患者,随机分为实验组和对照组,每组46例。对照组采用常规治疗,实验组在常规治疗的基础上加用丹参酮ⅡA磺酸钠注射液,比较两组患者的临床疗效。结果实验组患者的美国国立卫生院卒中量表(NIHSS)评分(10.8±3.4)分、神经功能缺损评分量表(NDS)评分(19.1±1.1)分均明显低于对照组的(15.2±5.3)、(25.3±1.2)分,日常生活活动能力Barthel指数(BI)(48.6±3.8)高于对照组的(35.1±3.6),差异均具有统计学意义(P<0.01)。实验组患者的血清丙二醛(MDA)、脂质过氧化物(LPO)、超氧化物歧化酶(SOD)分别为(8.2±0.6)mmol/ml、(9.8±2.1)mmol/ml、(6.1±0.2)U/ml,对照组患者的MDA、LPO、SOD分别为(10.5±0.5)mmol/ml、(13.3±2.6)mmol/ml、(4.8±0.1)U/ml,实验组患者的MDA、LPO水平低于对照组,SOD活性高于对照组,差异均具有统计学意义(t=19.973、7.103、39.431,P=0.000、0.000、0.000<0.01)。结论丹参酮ⅡA磺酸钠注射液应用于脑梗死的治疗中,能够改善神经功能缺损程度和日常生活能力,进一步提升脑梗死患者的治疗效果。
Objective To study the clinical effect of sodium tanshinone Ⅱ A sulfonate injection on cerebral infarction. Methods 92 patients with cerebral infarction were randomly divided into experimental group and control group, 46 cases in each group. The control group was treated with conventional therapy. The experimental group was given sodium tanshinone Ⅱ A sulfonate injection on the basis of routine treatment, and the clinical efficacy was compared between the two groups. Results The NIHSS score (10.8 ± 3.4) and NDS score (19.1 ± 1.1) in the experimental group were significantly lower than those in the control group (15.2 ± 5.3 ), (25.3 ± 1.2) points, Barthel index (BI) (48.6 ± 3.8) in daily life was higher than that in control group (35.1 ± 3.6), the difference was statistically significant (P <0.01). The levels of MDA, LPO and SOD in the experimental group were (8.2 ± 0.6) mmol / ml and (9.8 ± 2.1) mmol / ml, respectively 6.1 ± 0.2) U / ml. The levels of MDA, LPO and SOD in the control group were (10.5 ± 0.5) mmol / ml, (13.3 ± 2.6) mmol / ml and The levels of MDA and LPO were lower than those of the control group and SOD activity was higher than that of the control group (t = 19.973, 7.103, 39.431, P = 0.000,0.000,0.000 <0.01). Conclusion Sodium tanshinone Ⅱ A sulfonate injection can be used in the treatment of cerebral infarction, which can improve the degree of neurological deficits and daily living ability and further improve the therapeutic effect of patients with cerebral infarction.